United Therapeutics Corp [UTHR] stock prices are up 1.08% to $438.75 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The UTHR shares have gain 8.69% over the last week, with a monthly amount glided 43.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on June 02, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $405. Previously, Wells Fargo downgraded its rating to Equal Weight on April 25, 2025. On April 21, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $314 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and increased its price target to $321 on July 11, 2024. Goldman upgraded its rating to a Neutral and raised its price target to $215 on February 12, 2024. Leerink Partners started tracking with a Outperform rating for this stock on February 05, 2024, and assigned it a price target of $330. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $309 on this stock.
The stock price of United Therapeutics Corp [UTHR] has been fluctuating between $266.98 and $438.26 over the past year. Currently, Wall Street analysts expect the stock to reach $475.75 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $438.75 at the most recent close of the market. An investor can expect a potential return of 8.43% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
The United Therapeutics Corp [NASDAQ:UTHR] reported sales of 3.08B for trailing twelve months, representing a surge of 11.71%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.47%, Pretax Profit Margin comes in at 0.53%, and Net Profit Margin reading is 0.4%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.19 and Total Capital is 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 428.94 points at the first support level, and at 419.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 445.29, and for the 2nd resistance point, it is at 451.82.
Ratios To Look Out For
It’s worth pointing out that United Therapeutics Corp [NASDAQ:UTHR]’s Current Ratio is 7.26. As well, the Quick Ratio is 6.94, while the Cash Ratio is 3.02. Considering the valuation of this stock, the price to sales ratio is 6.45, the price to book ratio is 2.77 and price to earnings (TTM) ratio is 17.13.
Transactions by insiders
Recent insider trading involved CHRISTOPHER CAUSEY, Director, that happened on Sep 24 ’25 when 1000.0 shares were purchased. FOUNDER, CHAIRPERSON, AND CHIE, ROTHBLATT MARTINE A completed a deal on Sep 24 ’25 to buy 4000.0 shares. Meanwhile, PRESIDENT AND COO BENKOWITZ MICHAEL sold 22500.0 shares on Sep 22 ’25.
